Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01856842|
Recruitment Status : Recruiting
First Posted : May 17, 2013
Last Update Posted : May 18, 2017
AVMs are abnormal collections of blood vessels which can occur in any part of the body including the lungs. These blood vessels are weakened and can rupture anytime causing bleeding which can be massive, leading to life-threatening conditions.
Pulmonary AVMs occur in about 40% of patients with HHT. Each patient may have an average of 5 AVMs .Rupture of the AVM can lead to massive bleeding in the lung, stroke and infection of the brain. In order to prevent these complications, patients with HHT are routinely examined for pulmonary AVMs and treatment with embolization is recommended.
AVMs have a main blood vessel or artery supplying blood to the collection of blood vessels. The way to treat AVMs is cut off their blood supply through a process called embolization.
Embolization is a standard medical procedure which is done to stop or prevent hemorrhage (bleeding) from an AVM. It involves blocking the artery that supplies blood to the AVM by inserting a foreign body, into the blood vessel supplying blood to the AVM.
Standard devices used for embolization include coils (made of stainless steel or platinum). These devices usually have a good success rate for blocking the artery that supplies blood to the AVM. However, a few AVMs that are embolized by standard devices may reopen over time. This is called reperfusion and will require repeat embolization procedures.
For embolization of pulmonary AVMs at St. Michael's Hospital, the Nester coil is used. In this study, we would like to compare the Nester coil with a new coil device called the Interlock Fibered IDC Occlusion System. Both coils are approved for use in Canada, however the cost of the IDC coil limits its use at this hospital.
Compared to the Nester coil, the IDC coils are made so that they can be removed or repositioned if they are not placed correctly. The coil also allows tighter packing which helps prevent reperfusion.
This study will compare the success rate of embolization between the Interlock™ Fibered IDC™ Occlusion System (IDC coil) and the Nester coil.
|Condition or disease||Intervention/treatment|
|Pulmonary Arteriovenous Malformations||Procedure: Angiography and embolotherapy|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy. A Randomized Trial of Interlock™ Fibered IDC™ Occlusion System vs. Nester Coils|
|Study Start Date :||April 2013|
|Estimated Primary Completion Date :||April 2018|
|Estimated Study Completion Date :||April 2018|
Active Comparator: Interlock fibered IDC Occlusion System
Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
|Procedure: Angiography and embolotherapy|
Active Comparator: Nestor Coil
Pulmonary angiography and embolotherapy technique using Nestor coils
|Procedure: Angiography and embolotherapy|
- Difference in reperfusion rate [ Time Frame: 10-14 months post embolization ]The primary end-point for this study is the difference in reperfusion rate between the two treatment groups from procedure day to the final follow-up at 10-14 month post embolization, measured by the unenhanced CT Chest.
- Fluoroscopy/radiation time [ Time Frame: during procedure ]Fluoroscopy/radiation time
- Contrast volume required [ Time Frame: during embolization ]Contrast volume required
- Procedural time [ Time Frame: during embolization ]Procedural time
- Complication rates [ Time Frame: during embolization ]Complication rates
- Cost analysis [ Time Frame: during 10-14 months post procedure that is to final visit ]Cost analysis
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01856842
|Contact: Vikram Prabhudesai, MD||416 864 6060 ext firstname.lastname@example.org|
|St. Michael's Hospital||Recruiting|
|Toronto, Ontario, Canada, M5B 1W8|
|Principal Investigator: Vikram Prabhudesai, MD|
|Principal Investigator: Marie Faughnan, MD|
|Principal Investigator:||Vikram Prabhudesai, MD||St. Michael's Hospital, Toronto|
|Principal Investigator:||Marie Faughnan, MD||St. Michael's Hospital, Toronto|